Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 2 full-time employees. The company went IPO on 2004-07-19. The company develops and commercializes blood-based diagnostic products across multiple cancer indications. The firm's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. The company also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The firm is present in Europe and the United States.
Follow-Up Questions
What is the price performance of EPGNF stock?
The current price of EPGNF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Epigenomics AG?
Epigenomics AG belongs to Biotechnology industry and the sector is Health Care
What is Epigenomics AG market cap?
Epigenomics AG's current market cap is $0
Is Epigenomics AG a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Epigenomics AG, including 3 strong buy, 6 buy, 1 hold, 0 sell, and 3 strong sell
